Spero Therapeutics Inc
NASDAQ:SPRO

Watchlist Manager
Spero Therapeutics Inc Logo
Spero Therapeutics Inc
NASDAQ:SPRO
Watchlist
Price: 1.29 USD 9.32% Market Closed
Market Cap: 69.7m USD
Have any thoughts about
Spero Therapeutics Inc?
Write Note

Intrinsic Value

SPRO's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one SPRO stock under the Base Case scenario is 0.73 USD. Compared to the current market price of 1.29 USD, Spero Therapeutics Inc is Overvalued by 44%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

SPRO Intrinsic Value
0.73 USD
Overvaluation 44%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Spero Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for SPRO cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about SPRO?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Spero Therapeutics Inc

Provide an overview of the primary business activities
of Spero Therapeutics Inc.

What unique competitive advantages
does Spero Therapeutics Inc hold over its rivals?

What risks and challenges
does Spero Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Spero Therapeutics Inc recently?

Summarize the latest earnings call
of Spero Therapeutics Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Spero Therapeutics Inc.

Provide P/S
for Spero Therapeutics Inc.

Provide P/E
for Spero Therapeutics Inc.

Provide P/OCF
for Spero Therapeutics Inc.

Provide P/FCFE
for Spero Therapeutics Inc.

Provide P/B
for Spero Therapeutics Inc.

Provide EV/S
for Spero Therapeutics Inc.

Provide EV/GP
for Spero Therapeutics Inc.

Provide EV/EBITDA
for Spero Therapeutics Inc.

Provide EV/EBIT
for Spero Therapeutics Inc.

Provide EV/OCF
for Spero Therapeutics Inc.

Provide EV/FCFF
for Spero Therapeutics Inc.

Provide EV/IC
for Spero Therapeutics Inc.

Show me price targets
for Spero Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Spero Therapeutics Inc?

How accurate were the past Revenue estimates
for Spero Therapeutics Inc?

What are the Net Income projections
for Spero Therapeutics Inc?

How accurate were the past Net Income estimates
for Spero Therapeutics Inc?

What are the EPS projections
for Spero Therapeutics Inc?

How accurate were the past EPS estimates
for Spero Therapeutics Inc?

What are the EBIT projections
for Spero Therapeutics Inc?

How accurate were the past EBIT estimates
for Spero Therapeutics Inc?

Compare the revenue forecasts
for Spero Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Spero Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Spero Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Spero Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Spero Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Spero Therapeutics Inc with its peers.

Analyze the financial leverage
of Spero Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Spero Therapeutics Inc.

Provide ROE
for Spero Therapeutics Inc.

Provide ROA
for Spero Therapeutics Inc.

Provide ROIC
for Spero Therapeutics Inc.

Provide ROCE
for Spero Therapeutics Inc.

Provide Gross Margin
for Spero Therapeutics Inc.

Provide Operating Margin
for Spero Therapeutics Inc.

Provide Net Margin
for Spero Therapeutics Inc.

Provide FCF Margin
for Spero Therapeutics Inc.

Show all solvency ratios
for Spero Therapeutics Inc.

Provide D/E Ratio
for Spero Therapeutics Inc.

Provide D/A Ratio
for Spero Therapeutics Inc.

Provide Interest Coverage Ratio
for Spero Therapeutics Inc.

Provide Altman Z-Score Ratio
for Spero Therapeutics Inc.

Provide Quick Ratio
for Spero Therapeutics Inc.

Provide Current Ratio
for Spero Therapeutics Inc.

Provide Cash Ratio
for Spero Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Spero Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Spero Therapeutics Inc?

What is the current Free Cash Flow
of Spero Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Spero Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Spero Therapeutics Inc

Current Assets 122.2m
Cash & Short-Term Investments 63.5m
Receivables 55.5m
Other Current Assets 3.2m
Non-Current Assets 27.7m
PP&E 3.6m
Other Non-Current Assets 24m
Current Liabilities 45.6m
Accounts Payable 2.7m
Accrued Liabilities 11.7m
Other Current Liabilities 31.2m
Non-Current Liabilities 23.7m
Other Non-Current Liabilities 23.7m
Efficiency

Earnings Waterfall
Spero Therapeutics Inc

Revenue
118.5m USD
Operating Expenses
-102.9m USD
Operating Income
15.6m USD
Other Expenses
1.9m USD
Net Income
17.5m USD

Free Cash Flow Analysis
Spero Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

Spero Therapeutics ended Q2 2024 with $63.5 million in cash. Revenue climbed to $10.2 million from $2.7 million in Q2 2023. This rise was driven by increased collaboration and grant revenues, primarily from agreements with GSK and BARDA. However, R&D expenses surged to $23.7 million from $9.5 million, aimed at advancing key clinical trials. Spero expects its cash, along with milestone payments, to fund operations until late 2025. Additionally, the company anticipates top-line data from its pivotal trials by next year, indicating continued focus on advancing SPR720 and tebipenem HBr【4:0†source】.

What is Earnings Call?
Fundamental Scores

SPRO Profitability Score
Profitability Due Diligence

Spero Therapeutics Inc's profitability score is 35/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Exceptional 1-Year Revenue Growth
ROE is Increasing
ROIC is Increasing
35/100
Profitability
Score

Spero Therapeutics Inc's profitability score is 35/100. The higher the profitability score, the more profitable the company is.

SPRO Solvency Score
Solvency Due Diligence

Spero Therapeutics Inc's solvency score is 53/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Long-Term Solvency
Low Altman Z-Score
53/100
Solvency
Score

Spero Therapeutics Inc's solvency score is 53/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

SPRO Price Targets Summary
Spero Therapeutics Inc

Wall Street analysts forecast SPRO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SPRO is 7.65 USD with a low forecast of 7.07 USD and a high forecast of 8.4 USD.

Lowest
Price Target
7.07 USD
448% Upside
Average
Price Target
7.65 USD
493% Upside
Highest
Price Target
8.4 USD
551% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for SPRO?

Click here to dive deeper.

Dividends

Spero Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for SPRO is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

SPRO Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Spero Therapeutics Inc Logo
Spero Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

69.7m USD

Dividend Yield

0%

Description

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant, or MDR, bacterial infections. The company is headquartered in Cambridge, Massachusetts and currently employs 146 full-time employees. The company went IPO on 2017-11-02. The firm is focused on identifying, developing and commercializing novel treatments for MDR bacterial infections. Its lead product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide), is developed as the oral carbapenem antibiotic for use in complicated urinary tract infections (cUTI) and acute pyelonephritis (AP). The company is also developing SPR720 as a novel oral therapy product candidate for the treatment of rare, orphan pulmonary disease caused by non-tuberculous mycobacterial (NTM) infections. The firm also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform, which is being developed to treat MDR Gram-negative infections in the hospital setting.

Contact

MASSACHUSETTS
Cambridge
675 Massachusetts Ave Ste 14
+18572421600.0
sperotherapeutics.com

IPO

2017-11-02

Employees

146

Officers

Co-Founder & Chairman of the Board
Dr. Ankit Mahadevia M.D., MBA
President, CEO & Director
Mr. Satyavrat Shukla C.F.A.
Chief Operating Officer
Mr. Timothy Keutzer
CFO, Chief Business Officer & Treasurer
Ms. Esther P. Rajavelu
Chief Human Resource Officer
Mr. James P. Brady
Chief Medical Officer
Dr. Kamal Hamed M.B.A., M.D., M.P.H.

See Also

Discover More
What is the Intrinsic Value of one SPRO stock?

The intrinsic value of one SPRO stock under the Base Case scenario is 0.73 USD.

Is SPRO stock undervalued or overvalued?

Compared to the current market price of 1.29 USD, Spero Therapeutics Inc is Overvalued by 44%.

Back to Top